325 related articles for article (PubMed ID: 30234231)
1. [Hyperphosphatemia in dialysis: which binder?].
Alfieri C; Malberti F; Mazzaferro S; Gallieni M; Russo D; Messa P; Cozzolino M
G Ital Nefrol; 2018 Sep; 35(5):. PubMed ID: 30234231
[TBL] [Abstract][Full Text] [Related]
2. Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis.
Greig SL; Plosker GL
Drugs; 2015 Apr; 75(5):533-42. PubMed ID: 25761962
[TBL] [Abstract][Full Text] [Related]
3. The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis.
Ramos R; Chazot C; Ferreira A; Di Benedetto A; Gurevich K; Feuersenger A; Wolf M; Arens HJ; Walpen S; Stuard S
BMC Nephrol; 2020 Dec; 21(1):530. PubMed ID: 33287733
[TBL] [Abstract][Full Text] [Related]
4. Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence.
Coyne DW; Sprague SM; Vervloet M; Ramos R; Kalantar-Zadeh K
J Nephrol; 2022 Apr; 35(3):875-888. PubMed ID: 35138627
[TBL] [Abstract][Full Text] [Related]
5. Sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
Sprague SM; Floege J
Expert Opin Pharmacother; 2018 Jul; 19(10):1137-1148. PubMed ID: 29985725
[TBL] [Abstract][Full Text] [Related]
6. A review of sucroferric oxyhydroxide for the treatment of hyperphosphatemia in patients receiving dialysis.
Bousher A; Al-Makki A; Sutton J; Shepler B
Clin Ther; 2014 Dec; 36(12):2082-2093. PubMed ID: 25450474
[TBL] [Abstract][Full Text] [Related]
7. One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis.
Floege J; Covic AC; Ketteler M; Mann J; Rastogi A; Spinowitz B; Rakov V; Lisk LJ; Sprague SM
Nephrol Dial Transplant; 2017 Nov; 32(11):1918-1926. PubMed ID: 28339993
[TBL] [Abstract][Full Text] [Related]
8. A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
Sprague SM; Ketteler M
Expert Opin Drug Saf; 2021 Dec; 20(12):1463-1472. PubMed ID: 34511018
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.
Floege J; Covic AC; Ketteler M; Mann JF; Rastogi A; Spinowitz B; Chong EM; Gaillard S; Lisk LJ; Sprague SM;
Nephrol Dial Transplant; 2015 Jun; 30(6):1037-46. PubMed ID: 25691681
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of sucroferric oxyhydroxide treatment in Japanese hemodialysis patients and its effect on gastrointestinal symptoms.
Suzuki D; Ichie T; Hayashi H; Sugiura Y; Sugiyama T
Pharmazie; 2017 Feb; 72(2):118-122. PubMed ID: 29441865
[TBL] [Abstract][Full Text] [Related]
11. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.
Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ
Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935
[TBL] [Abstract][Full Text] [Related]
12. One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis.
Kendrick J; Parameswaran V; Ficociello LH; Ofsthun NJ; Davis S; Mullon C; Kossmann RJ; Kalantar-Zadeh K
J Ren Nutr; 2019 Sep; 29(5):428-437. PubMed ID: 30679076
[TBL] [Abstract][Full Text] [Related]
13. Iron-based phosphate binders--a new element in management of hyperphosphatemia.
Pai AB; Jang SM; Wegrzyn N
Expert Opin Drug Metab Toxicol; 2016; 12(1):115-27. PubMed ID: 26572591
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide.
Cozzolino M; Funk F; Rakov V; Phan O; Teitelbaum I
Curr Drug Metab; 2014; 15(10):953-65. PubMed ID: 25658128
[TBL] [Abstract][Full Text] [Related]
15. [Sucroferric oxyhydroxide, a novel iron-based phosphate binder. Which current use in dialysis patients?].
Bataille P; Delattre V; Daroux M
Nephrol Ther; 2017 Apr; 13 Suppl 1():S103-S108. PubMed ID: 28577730
[TBL] [Abstract][Full Text] [Related]
16. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
[TBL] [Abstract][Full Text] [Related]
17. Rationale, design, and characteristics of a trial to evaluate the new phosphate iron-based binder sucroferric oxyhydroxide in dialysis patients with the goal of advancing the practice of E.B.M. (EPISODE).
Isaka Y; Fujii H; Tsujimoto Y; Teramukai S; Hamano T
Clin Exp Nephrol; 2018 Aug; 22(4):967-972. PubMed ID: 29536389
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study.
Covic AC; Sprague SM; Rastogi A; Ketteler M; Walpen S; Perrin A; Floege J
Nephron; 2020; 144(9):428-439. PubMed ID: 32585670
[TBL] [Abstract][Full Text] [Related]
19. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients.
Ketteler M; Sprague SM; Covic AC; Rastogi A; Spinowitz B; Rakov V; Walpen S; Floege J
Nephrol Dial Transplant; 2019 Jul; 34(7):1163-1170. PubMed ID: 29846719
[TBL] [Abstract][Full Text] [Related]
20. Optimal Phosphate Control Related to Coronary Artery Calcification in Dialysis Patients.
Isaka Y; Hamano T; Fujii H; Tsujimoto Y; Koiwa F; Sakaguchi Y; Tanaka R; Tomiyama N; Tatsugami F; Teramukai S
J Am Soc Nephrol; 2021 Mar; 32(3):723-735. PubMed ID: 33547218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
